Stay updated on NBI-1117568 in Schizophrenia: Efficacy, Safety & PK Clinical Trial

Sign up to get notified when there's something new on the NBI-1117568 in Schizophrenia: Efficacy, Safety & PK Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NBI-1117568 in Schizophrenia: Efficacy, Safety & PK Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy, safety, tolerability, and pharmacokinetics assessment of NBI-1117568 compared with placebo in adults with schizophrenia in a Phase 2 clinical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:49.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as informed consent, a primary diagnosis of schizophrenia, and the need for hospitalization due to acute exacerbation or relapse of symptoms. This change provides more specific information about the inclusion and exclusion criteria for the study.
    Difference
    17%
    Check dated 2024-05-22T20:54:46.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:23:38.000Z thumbnail image

Stay in the know with updates to NBI-1117568 in Schizophrenia: Efficacy, Safety & PK Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NBI-1117568 in Schizophrenia: Efficacy, Safety & PK Clinical Trial page.